Explicyte Immuno-Oncology

What do we do at Explicyte Immuno-Oncology? Alban Bessede, PhD, founder and CEO of Explicyte, provides a quick overview in 90 seconds. #Preclinical #Translational #Research #Cancer #Immunotherapy #CRO

#AACR #IO Meet our CSO Imane Nafia in Los Angeles, CA! Yesterday she presented a poster on #OvarianAscites. Today she'll be discussing another poster: "Enhanced anti-tumor response to anti-angiogenic / hypoxia-regulating therapies in combination with immune checkpoint blockade in a murine model of renal carcinoma" - poster B074, 1:45-4:45pm American Association for Cancer Research

#Webinar #ImmunoOncology March 27: "Tertiary Lymphoid Structures (TLS) & Cancer Immunotherapy: Inducing TLS & Addressing Resistance Mechanisms" Register here: https://lnkd.in/dHjX_rSv Join us for an insightful session featuring the first authors behind three influential 2025 papers on tertiary lymphoid structures (TLS) in cancer. Masataka Amisaki, MD, PhD, Memorial Sloan Kettering Cancer Center (USA): Presenting a groundbreaking 2025 Nature paper, "IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer". Dr. Amisaki’s work deepens our understanding of TLS biology and paves the way for innovative therapeutic strategies for transforming “cold” tumors into immunologically active environments. Read paper: https://lnkd.in/gEeJg5dF Florent Peyraud, MD, PhD, Institut Bergonié (France) Sharing findings from his PhD research, conducted at Explicyte, Dr. Peyaud will discuss 2 publications: > A research paper in Cell Reports Medicine titled "Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures" Read paper: https://lnkd.in/dvdRTzD2 > A comprehensive review in Med. titled "Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside". Read paper: https://lnkd.in/dCGu_HWg Session Introduction: Immunologist Alban Bessede, PhD, CEO of Explicyte Immuno-Oncology, will kick off the session. Dr Bessede has been working on TLS since 2020, co-authoring foundational papers in Nature Cancer and Nature Medicine on TLS & immune-checkpoint inhibitors, and is now developing accredited pathology services for detecting and scoring TLS in tumor specimens to support precision oncology initiatives. Italiano Antoine Vinod Balachandran Tullia Bruno

#NewPaper in Cell Reports Medicine by Cell Press: Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures (#TLS) Full text: https://lnkd.in/dV6Dr3kp This translational research paper highlights the work of Florent Peyraud, MD, conducted during his PhD thesis at Explicyte Immuno-Oncology under the supervision of Prof. Italiano Antoine (Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers) and Alban Bessede, PhD (Explicyte). This project was made possible thanks to a collaboration with the imCORE network (Roche/Genentech), and samples from the BIP trial (NCT02534649). The study aims to uncover why certain patients with non-small cell lung cancer (NSCLC) who exhibit mature tertiary lymphoid structures (mTLS)—a phenotype typically associated with a favorable response to immune checkpoint inhibitors (ICI)—do not respond to anti-PD1/PD-L1 immunotherapy. By combining pathology, digital pathology, spatial transcriptomics (GeoMx DSP), and bulk transcriptomics, the study identifies subsets of cancer-associated fibroblasts (#CAFs)—namely, FAP⁺αSMA⁺ and MYH11⁺αSMA⁺ cells—that play a crucial role in mediating primary resistance to immune-checkpoint inhibitors in NSCLC patients with mature TLS. Congrats to Florent Peyraud (again!), our translational team, and thanks to all contributors! Jean-Philippe Guégan, Christophe REY, Oren Lara, Marie Del Castillo, Lucile Vanhersecke, Jean Michel Coindre, Emma Clot, Maxime Brunet, Thomas GRELLETY, Angélique Tasseel Sylvestre Le Moulec, Robert Johnston, CENTRE HOSPITALIER DE LA COTE BASQUE, Université de Bordeaux, Atlantic Pathologie Polyclinique Marzet Interested in the assessment of TLS maturity? Learn about Explicyte's histopathology services for TLS detection & evaluation in tumor specimens: https://lnkd.in/dvuMa4-f

✨ Proud and thrilled to have my PhD thesis work published in the January issue of Cell Reports Medicine by Cell Press Cell Press about the impact of TLS in lung cancer treated with immunotherapy. 👇🏻 🔬 Decoding ICI Response in NSCLC: The Role of CAFs in mTLS-Positive Tumors 💉Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for non-small cell lung cancer (NSCLC), with mature tertiary lymphoid structures (mTLSs) emerging as key predictors of response. However, not all mTLS-positive tumors benefit from ICIs, emphasizing the need to identify additional determinants of response and resistance. In our analysis of 509 ICI-treated NSCLC patients from the Bergonié Institute Profiling (BIP) study (NCT02534649), we found that mTLSs correlate with improved clinical outcomes, independent of PD-L1 expression and genomic features. But what drives primary resistance in some mTLS-positive tumors? Using spatial transcriptomics and multiplex immunofluorescence (mIF), we uncovered two distinct cancer-associated fibroblast (CAF) subsets that play a crucial role in mediating resistance to ICIs: 🧬 FAP⁺αSMA⁺ CAFs → Associated with immune exclusion and CD8⁺ T cell exhaustion, potentially impairing ICI efficacy. 🛑 MYH11⁺αSMA⁺ CAFs → Contribute to an immunosuppressive TME, fostering regulatory CD4⁺ T cell (Treg) infiltration and further dampening anti-tumor immunity. 💡 Key Takeaway: The presence of specific CAF subsets can counteract the benefits of mTLSs, revealing new therapeutic targets to overcome resistance and enhance ICI efficacy. 🔗 https://lnkd.in/eUtPQQwK #Immunotherapy #LungCancer #NSCLC #TumorMicroenvironment #CancerResearch #SpatialBiology #CAF 🙏🏻A huge thank you to all the co-authors Christophe REY Oren Lara Ophélie Odin Marie Del Castillo Lucile Vanhersecke Jean Michel Coindre Emma Clot Maxime Brunet Thomas GRELLETY Angélique Tasseel Sylvestre Le Moulec Robert Johnston, with a special thank to Jean-Philippe Guégan for its invaliable help, and to my two thesis advisors Alban Bessede, PhD Italiano Antoine. 💪🏻 A great example of collaborative work between the Institut Bergonié Unicancer and Explicyte Immuno-Oncology, supported by the Dispositif Cifre program and Université de Bordeaux. 🗞️ Check the January issue from #CellReportsMedicine. See below to access the full issue here👇🏻: https://lnkd.in/eX-f-QBv 📝 Let’s also take a look at the review on TLS and immunotherapy in cancer, which is related to my PhD work, published in Med by Cell Press: https://lnkd.in/dDsQZmgp

#OpenPosition #3D #CellCulture #TumorModels in #Bordeaux - Apply: https://lnkd.in/d5JStcvf You are passionate about the interplay between immune and tumor cells? You have experience with 3D tumor-based culture models in the perspective of testing innovative cancer immunotherapies? You are proficient in flow cytometry and multiparametric platforms for in vitro/ex-vivo analyses? Join us !

#OpenPosition #SingleCell #DataScientist #Bordeaux #France You like to play with large multi-omics datasets and analyze spatial information? You have an interest in the biological processes involved in the response to cancer immunotherapies? Apply! https://lnkd.in/dkr-brVj

Review on #TLS and #CancerImmunotherapy in Med by Cell Press! https://lnkd.in/digJp9B6 We’re excited to share this comprehensive review on Tertiary Lymphoid Structures (TLS), highlighting the work of Florent Peyraud, an oncologist from the Institut Bergonié. Florent completed his PhD thesis at Explicyte Immuno-Oncology under the guidance of Italiano Antoine (Institut Bergonié/Gustave Roussy). Congratulations, Florent! This review delves into recent advancements in TLS research, covering: > TLS composition, maturation status, and prevalence across tumor types > The role of TLS in antitumor immunity and prognosis, including their predictive value in response to immunotherapy > Therapeutic strategies: drivers of TLS formation, relevant preclinical models, and the induction of TLS using cytokines, chemokines, or existing cancer treatments. Learn more about the expertise of our translational team in TLS detection and scoring, combining digital pathology and pathologist-assisted image analysis: https://lnkd.in/dvuMa4-f

#ImmuneCells #Tumor #Killing #Assays How to assess drug candidates enhancing the functions of effector cells against cancer cells? Here a quick overview of our specialized killing assays for #ImmunoOncology: https://lnkd.in/dgBm-u5u

#SingleCell #Spatial #Transcriptomics Last days to book your slot on the Xenium platform with the human #ImmunoOncology panel at a special price! Contact us before the 20th of December: https://lnkd.in/dtPS_z6f